Navigation Links
BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors
Date:1/15/2014

NEW YORK, January 15, 2014 /PRNewswire/ --

BreedIT Corp (OTC: BRDT), through its Israeli subsidiary, BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding solutions for plant breeders and researchers, today announced that on January 7, 2014, the Company's board of directors appointed chemistry and pharmaceutical industry expert Dr. Ben-Zion Weiner as its new member of the board.

From 1975 to 2012, Dr. Weiner held executive positions with Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and its subsidiaries ("Teva"). He was Vice President of Global Products of Teva from 2005 to 2011 where he was responsible for global Generic and Innovative Research and Development.

Dr. Weiner was also a Member of the Core Management Committee.

Dr. Weiner holds a B.Sc. Degree in General Chemistry and Biochemistry, graduating with distinction at the Hebrew University, Jerusalem, a M.Sc. Degree in Organic Chemistry, graduating with distinction at the Hebrew University of Jerusalem, and a Ph.D. Degree from the Hebrew University, Jerusalem. Dr. Weiner did his Post-Doctorate studies at Schering Plough Corporation in Bloomfield, New Jersey, on "Exploratory work of new drugs, research in organic chemistry, and pharmacology." Notable accolades include receiving the Rothschild Prize for Innovation/Export for the development of Copaxone(R) for Multiple Sclerosis and for the development of alpha D3 for Dialysis and Osteoporosis.

Dr. Weiner commented, "I am  pleased with the high potential of BreedIT's technology. My pharmaceutical background will allow me to consult and advise how to maximize future products potential uses, especially in the efforts to pursue opportunities in the Medical Cannabis field."

Itschak Shrem, Chairman of BreedIT Corp., stated, "I would like to officially welcome Dr. Weiner to our board of directors. His qualifications and expertise in the areas of chemistry, pharmacology and pharmaceutical products will undoubtedly be of significant value as we explore our potential in medicinal cannabis and other opportunities."

About BreedIT Corp

BreedIT Corp (OTC: BRDT), through its Israeli subsidiary, BreedIT Ltd., is the exclusive world wide distributor of highly sophisticated agro-breeding solutions for plant breeders and researchers. BreedIT's proven Intelligent Decision Support System (the "IDSS Software"), which was developed by a team consisting of among the world's leading breeding specialists for optimizing the breeding processes, services the plant breeders, researchers and governmental institutions. BreedIT's IDSS provides advanced solutions for generating and disseminating knowledge aimed at assisting breeders to plan, manage and analyze their breeding data and to perform research activities quickly and effectively. Founded in 2010, BreedIT has offices in New York, New York and in Rehovot, Israel.

Forward-Looking Statements:

This press release may contain forward-looking statements, including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including but not limited to, its Form 10-K, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company.  In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.* BreedIt Corp's public filings may be viewed at http://www.sec.gov/.

Investor Relations:

Howard Gostfrand
info@amcapventures.com
+1-305-918-7000


'/>"/>
SOURCE BreedIT Corp
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Businessmen Bank on Marijuana as Colorados Green Rush Approaches in the Medical Marijuana Industry with Hemp, Inc. (OTC: HEMP) Leading the Charge
2. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
3. Tegra Medical Appoints New Chief Executive Officer
4. Meditope Biosciences Appoints Prominent Scientific Advisory Board
5. Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
6. Analyte Health Appoints Lawrence Leisure to its Advisory Board
7. ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer
8. Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
9. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
10. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
11. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed ... 39 states and Washington, D.C. as ... move that was commended by shareholder advocacy organization As You ... As You Sow. "Many people hold on to unneeded drugs ... can have tragic consequences." --> Conrad MacKerron ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... “ HEALING MIND ... through a Well Managed Mind” (published by Balboa Press) teaches readers how to become ... being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how ...
(Date:2/11/2016)... Oregon (PRWEB) , ... February 11, 2016 , ... ... campus participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, ... Match Program places students into osteopathic graduate medical education positions across the country. ...
(Date:2/11/2016)... Tampa, FL (PRWEB) , ... February 11, 2016 , ... ... Tampa Bay Lightning take on the St. Louis Blues at the Amalie Arena. The ... only portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The ...
(Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric ... to improve care by making data on heart procedures public and easily understandable ... Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes will bring ...
Breaking Medicine News(10 mins):